Cooper Companies (NASDAQ:COO) Upgraded at Wall Street Zen

Cooper Companies (NASDAQ:COO) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Sunday.

A number of other analysts have also weighed in on the stock. Barclays increased their price objective on shares of Cooper Companies from $98.00 to $103.00 and gave the stock an “overweight” rating in a research note on Friday, March 6th. KeyCorp restated a “sector weight” rating on shares of Cooper Companies in a research report on Friday, June 5th. Weiss Ratings lowered shares of Cooper Companies from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, June 8th. JPMorgan Chase & Co. cut their price target on Cooper Companies from $80.00 to $71.00 and set a “neutral” rating on the stock in a research report on Friday, June 5th. Finally, BNP Paribas Exane reduced their price objective on Cooper Companies from $95.00 to $92.00 and set an “outperform” rating for the company in a research note on Monday, June 8th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, five have issued a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $81.31.

Cooper Companies Stock Performance

Cooper Companies stock opened at $65.91 on Friday. The stock has a 50-day moving average price of $64.39 and a 200 day moving average price of $73.96. The company has a market capitalization of $12.85 billion, a price-to-earnings ratio of 55.86, a price-to-earnings-growth ratio of 1.72 and a beta of 0.87. Cooper Companies has a 52 week low of $58.89 and a 52 week high of $89.83. The company has a quick ratio of 0.78, a current ratio of 1.27 and a debt-to-equity ratio of 0.23.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings results on Thursday, June 4th. The medical device company reported $1.21 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.11. Cooper Companies had a net margin of 5.57% and a return on equity of 10.88%. The company had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.05 billion. During the same quarter in the prior year, the company earned $0.96 EPS. Cooper Companies’s quarterly revenue was up 7.9% on a year-over-year basis. Cooper Companies has set its FY 2026 guidance at 4.580-4.660 EPS. Sell-side analysts anticipate that Cooper Companies will post 4.63 EPS for the current year.

Institutional Investors Weigh In On Cooper Companies

Hedge funds and other institutional investors have recently made changes to their positions in the company. Wellington Management Group LLP grew its position in Cooper Companies by 332.9% during the third quarter. Wellington Management Group LLP now owns 6,184,992 shares of the medical device company’s stock valued at $424,043,000 after buying an additional 4,756,178 shares during the period. Generation Investment Management LLP acquired a new position in shares of Cooper Companies in the fourth quarter worth about $233,539,000. Diamond Hill Capital Management Inc. raised its position in shares of Cooper Companies by 479.6% in the fourth quarter. Diamond Hill Capital Management Inc. now owns 3,287,837 shares of the medical device company’s stock worth $269,471,000 after acquiring an additional 2,720,594 shares during the period. JANA Partners Management LP purchased a new stake in shares of Cooper Companies during the 3rd quarter worth about $166,917,000. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Cooper Companies by 58.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,028,821 shares of the medical device company’s stock worth $494,123,000 after acquiring an additional 2,231,568 shares in the last quarter. Institutional investors and hedge funds own 24.39% of the company’s stock.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.